Business Context and Reporting Period
This Form 8-K Current Report was filed by SANUWAVE Health, Inc. on May 20, 2020, covering events occurring on May 14, 2020. The Company, incorporated in Nevada and trading on the OTCQB under the symbol SNWV, reported the entry into a definitive material agreement regarding a private placement of equity securities.
Key Financial Metrics and Transaction Details
- Capital Raised: $200,000 aggregate purchase price.
- Instrument: 8 shares of Series D Convertible Preferred Stock.
- Stated Value: $25,000 per share.
- Conversion Rate: $0.14 per share of Common Stock.
- Potential Dilution: Up to 1,428,571 shares of Common Stock upon full conversion.
- Financial Performance: The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period.
Material Changes and Transaction Terms
The Company entered into a Series D Preferred Stock Purchase Agreement with accredited investors. The transaction was exempt from registration under Section 4(a)(2) of the Securities Act of 1933. A critical material change involves the conversion mechanics: the Series D Preferred Stock is currently not convertible because the Company lacks sufficient authorized and unissued Common Stock.
Conversion is contingent upon the Company amending its Articles of Incorporation to increase authorized shares. Investors have agreed to convert their shares within five business days following such an amendment.
Outlook, Risks, and Contingencies
Authorization Failure Contingency: If the Company fails to obtain shareholder approval to amend its Articles of Incorporation to permit conversion by December 31, 2020, an "Authorization Failure" will occur. In this event, the Company must redeem all outstanding Series D Preferred Stock within 30 days.
Redemption Price: The redemption price per share will be the greater of:
- 200% of the stated value ($50,000 per share).
- The volume-weighted average sale price of Common Stock for the 30 trading days preceding the failure, multiplied by the number of Common Stock shares the Preferred Stock would have converted into.
Risk: The potential redemption obligation could impose a significant cash liability on the Company if the capital increase is not approved by the deadline.
Investor Verification Checklist
- Verify the Company's current authorized share count and the status of any pending amendments to the Articles of Incorporation.
- Confirm the timeline for shareholder approval required to enable conversion of the Series D Preferred Stock.
- Assess the Company's liquidity position relative to the potential redemption obligation (up to $400,000 or more based on market price) if the December 31, 2020 deadline is missed.
- Review the full text of the Certificate of Designation (Exhibit 3.1) and Purchase Agreement (Exhibit 10.1) for additional adjustment provisions.